Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

Journal Articles

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

Scott Kristian Jew, BS, Tiffany Chang, BS, Sean Elliott Bujarski, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Tahmineh Safaie, Mingjie Li, BS, Eric Sanchez, BA, Cathy S. Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4393.

https://doi.org/10.1182/blood-2019-132013

Published: 2019

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ning Xu, PhD, Nicole Ng, BS, Mingjie Li, BS, Erin Yu, BS, Eric Sanchez, BA, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1824.

https://doi.org/10.1182/blood-2019-131047

Published: 2019

Journal Articles

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

Sean Bujarski, BA, Camilia Soof, BS, Mingjie Li, BS, Cathy S. Wang, BS, Eric Sanchez, BA, Marsiye Emamy-Sadr, Regina Swift, Kian Rahbari, Saurabh Patil, BS, Tanya M. Spektor, PhD, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2018) 132 (Supplement 1): 1894.

https://doi.org/10.1182/blood-2018-99-119190

Published: 2018

Journal Articles

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia M. Soof, BS, Sean Bujarski, BA, Nicole Ng, Jasmin Cao, BS, Tara Hekmati, BS, Edward J Tanenbaum, BS, Brian Zahab, Cathy S. Wang, BS, George Y Tang, PhD, Ning Xu, PhD, James R Berenson, MD

Blood (2018) 132 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2018-99-119099

Published: 2018

Journal Articles

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Eric Sanchez, BA, Mingjie Li, BS, Cathy S Wang, BS, Edward J Tanenbaum, BS, Saurabh Patil, BS, Camilia Soof, BS, Tara Hekmati, BS, Remy E Schlossberg, BS, Moryel A Yashar, BS, Autumn L Porter, BS, George Y Tang, PhD, Haiming Chen, MD PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 5393.

https://doi.org/10.1182/blood.V130.Suppl_1.5393.5393

Published: 2017

Journal Articles

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Camilia Soof, BS, Saurabh Patil, BS, Kyle Udd, BA, Mizi Zhou, MS, Tara Hekmati, BS, Emily Y Wang, Edward J Tanenbaum, BS, Remy Schlossberg, Moryel A Yashar, BS, Cathy S Wang, BS, George Y Tang, PhD, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 5390.

https://doi.org/10.1182/blood.V130.Suppl_1.5390.5390

Published: 2017

Journal Articles

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 4413.

https://doi.org/10.1182/blood.V130.Suppl_1.4413.4413

Published: 2017

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, James R Berenson, MD

Blood (2017) 130 (Supplement 1): 4371.

https://doi.org/10.1182/blood.V130.Suppl_1.4371.4371

Published: 2017

Journal Articles

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Kyle Udd, BA, Haiming Chen, MD PhD, Mingjie Li, BS, Camilia M Soof, BS, Christian Casas, BS, Soudabeh Etessami, PhD, Zachary Gross, MD, Matthew Ghermezi, James Wang, Eric Sanchez, BA, Cathy S Wang, BS, Marsiye Emamy-Sadr, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5654.

https://doi.org/10.1182/blood.V128.22.5654.5654

Published: 2016

Journal Articles

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo

Eric Sanchez, BA, Mingjie Li, BS, Cathy S Wang, BS, Puja Mehta, BS, George Tang, PhD, Haiming Chen, MD PhD, James Berenson, MD

Blood (2016) 128 (22): 3297.

https://doi.org/10.1182/blood.V128.22.3297.3297

Published: 2016

Journal Articles

Gene Expression of Gamma Secretase (GS) Complex-Related Proteins, the Enzyme That Sheds B-Cell Maturation Antigen (BCMA), Among Patients with Multiple Myeloma (MM) and Effects of the GS Inhibitor LSN424354 on Solubilized Bcma in MM and Chronic Lymphocytic Leukemia

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Cathy S Wang, BS, Kyle A Udd, BA, Camilia M Soof, BS, Christian E Casas, BS, Jessica Wang, MS, Jasmin Cao, Kevin DeCorso, Tara Hekmati, George Tang, PhD, James R. Berenson, MD

Blood (2016) 128 (22): 5641.

https://doi.org/10.1182/blood.V128.22.5641.5641

Published: 2016

Journal Articles

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Zachary Gross, MD, Kyle Udd, BA, Matthew Ghermezi, Soudabeh Etessami, PhD, Haiming Chen, MD PhD, Tanya M. Spektor, PhD, Mingjie Li, BS, George Tang, PhD, Cathy S Wang, BS, Eric Sanchez, BA, Camilia M Soof, BS, Christian E Casas, BS, Regina Swift, RN, James R. Berenson, MD

Blood (2016) 128 (22): 5652.

https://doi.org/10.1182/blood.V128.22.5652.5652

Published: 2016

Journal Articles

Carfilzomib Platform Study Using The LAGκ-1A Multiple Myeloma Xenograft Model

Eric Sanchez, Mingjie Li, Suzie Vardanyan, Jillian Gottlieb, Kevin Delijani, Joseph Ben-Zvi, Mitchell Song, Ran Halleluyan, Cathy S Wang, Haiming Chen, MD., Ph.D, James R. Berenson, MD

Blood (2013) 122 (21): 4452.

https://doi.org/10.1182/blood.V122.21.4452.4452

Published: 2013

Journal Articles

Decreased LIMD1 Gene Expression Is Associated with HIF-1α Over-Expression and Angiogenesis in Multiple Myeloma

Haiming Chen, MD., Ph.D, Jennifer Li, Kevin Delijani, Danielle Rauch, Kevin DeCorso, Andrew Prajogi, Cathy S Wang, Eric Sanchez, Benjamin Bonavida, Ph.D, James R. Berenson, MD

Blood (2012) 120 (21): 1829.

https://doi.org/10.1182/blood.V120.21.1829.1829

Published: 2012

Journal Articles

Anti-Myeloma Effects of the Janus Kinase 2 (JAK2) Inhibitor SAR503 Alone and in Combination Treatment

Haiming Chen, MD., Ph.D, Mingjie Li, Jennifer Li, Kevin Delijani, Danielle Rauch, Kevin DeCorso, Andrew Prajogi, Cathy S Wang, Eric Sanchez, Benjamin Bonavida, Ph.D, James R. Berenson, MD

Blood (2012) 120 (21): 4986.

https://doi.org/10.1182/blood.V120.21.4986.4986

Published: 2012

Journal Articles

Serum Levels of B-Cell Maturation Antigen Are Elevated in Multiple Myeloma Patients and Correlate with Disease Status and Overall Survival

Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy S Wang, Danielle Rauch, Kevin Delijani, Kevin DeCorso, Andrew Prajogi, Haiming Chen, MD., Ph.D, James R. Berenson, MD

Blood (2012) 120 (21): 4026.

https://doi.org/10.1182/blood.V120.21.4026.4026

Published: 2012

Journal Articles

TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma

Mingjie Li, Marissa P Dreyer, Cameryn P Ahles, David Ramirez, Cydney M Nichols, Tiffany Lee, More Song, Cathy S Wang, Eric Sanchez, Haiming Chen, Benjamin Bonavida, Ph.D, James R. Berenson, MD

Blood (2011) 118 (21): 2919.

https://doi.org/10.1182/blood.V118.21.2919.2919

Published: 2011

NARROW

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone

The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids

Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the Lagκ-1A Multiple Myeloma Xenograft Model

Effects of the Gamma Secretase Inhibitors (GSI) Dapt (GSI-IX) and LSN424354 on Gene Expression and Shedding of Bcma from Multiple Myeloma and Chronic Lymphocytic Leukemia Tumor Cells

Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma

Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments

Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo

Gene Expression of Gamma Secretase (GS) Complex-Related Proteins, the Enzyme That Sheds B-Cell Maturation Antigen (BCMA), Among Patients with Multiple Myeloma (MM) and Effects of the GS Inhibitor LSN424354 on Solubilized Bcma in MM and Chronic Lymphocytic Leukemia

Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival

Carfilzomib Platform Study Using The LAGκ-1A Multiple Myeloma Xenograft Model

Decreased LIMD1 Gene Expression Is Associated with HIF-1α Over-Expression and Angiogenesis in Multiple Myeloma

Anti-Myeloma Effects of the Janus Kinase 2 (JAK2) Inhibitor SAR503 Alone and in Combination Treatment

Serum Levels of B-Cell Maturation Antigen Are Elevated in Multiple Myeloma Patients and Correlate with Disease Status and Overall Survival

TRAF6 Dominant Negative Peptides Block Intracellular Signaling Resulting in Anti-Myeloma and Anti-Bone Resorptive Effects in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only